国产日产欧美精品-亚洲国产综合久久精品-色综合色国产热无码一-亚洲欧美日本国产,免费观看一区二区三区_在线观看片A免费不卡观看_亚洲а∨天堂久久精品_99久无码中文字幕一本久道

產(chǎn)品展廳收藏該商鋪

您好 登錄 注冊(cè)

當(dāng)前位置:
美國(guó)布魯克海文儀器公司>技術(shù)文章>Nanobrook Omni測(cè)量應(yīng)用案例-32

技術(shù)文章

Nanobrook Omni測(cè)量應(yīng)用案例-32

閱讀:323          發(fā)布時(shí)間:2018-8-13
 文獻(xiàn)名:Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer 

 

作者:Tanaya Vaidya1, Robert M. Straubinger2, Sihem Ait-Oudhia1 

    1.Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy University of Florida, Orlando, USA

    2.Department of Pharmaceutical Sciences University at Buffalo, State University of New York, Buffalo, USA

 

摘要:

Purpose

Trastuzumab combined with Doxorubicin (DOX) demonstrates significant clinical activity in human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC). However, emergence of treatment resistance and trastuzumab associated cardiotoxicity remain clinical challenges. In an effort to improve patient outcome, we have developed and evaluated novel tri-functional immunoliposomes (TFIL) that target HER2-receptors on BC cells and CD3-receptors on T-lymphocytes, and deliver DOX.

 

Methods

Trastuzumab (anti-HER2) and OKT-3 (anti-CD3) antibodies were conjugated to liposomes using a micelle-transfer method. Cytotoxicity of targeted immunoliposomes loaded with DOX was examined in vitro on HER2-positive BC cells (BT474), with peripheral blood monocytic cells (PBMC) as immune effector cells.

 

Results

TFIL demonstrated high antibody-liposome conjugation ratios (100130 μg protein/μmol phospholipid) and cargo capacity (0.21 mol:mol drug:lipid), highly efficient DOX loading (>90%), a particle size favorable for extended circulation (~150 nm), and good stability (up to 3 months at 4°C). In the presence of PBMCs, TFIL showed complete killing of BT474 cells, and were superior to mono-targeted trastuzumab-bearing liposomes, non-targeted liposomes, and free Trastuzumab and DOX.

 

Conclusions

Novel anti-HER2xCD3+DOX TFIL show promise as a means to both engage immune cells against HER2 positive breast cancer cells and deliver chemotherapy, and have the potential to improve clinical outcomes.

收藏該商鋪

請(qǐng) 登錄 后再收藏

提示

您的留言已提交成功!我們將在第一時(shí)間回復(fù)您~

對(duì)比框

產(chǎn)品對(duì)比 產(chǎn)品對(duì)比 聯(lián)系電話 二維碼 意見(jiàn)反饋 在線交流

掃一掃訪問(wèn)手機(jī)商鋪
010-62081908
在線留言
东安县| 讷河市| 桂阳县| 玉环县| 崇州市| 桂阳县| 株洲县| 麦盖提县| 崇信县| 边坝县| 天门市| 顺平县| 雅安市| 汝南县| 美姑县| 龙门县| 满洲里市| 阳新县| 盐源县| 星子县| 麻江县| 夹江县| 环江| 隆昌县| 尤溪县| 剑阁县| 泽库县| 榆社县| 游戏| 烟台市| 张家口市| 普定县| 公安县| 田林县| 湖口县| 格尔木市| 习水县| 静安区| 桦甸市| 镇平县| 惠东县|